96.5 F
San Fernando
Friday, Mar 29, 2024

Amgen Announces Positive Results for Phase 2 Study of Aranesp

Thousand Oaks-based biotechnology company, Amgen found from a Phase 2 study that their drug, Aranesp, used to treat patients with symptomatic heart failure and anemia, was well tolerated. Results from several Phase 2 tests revealed that Aranesp raised hemoglobin, decreased the risk of heart failure, hospitalization and mortality, and improved symptoms. These results will have to be confirmed in Phase 3 clinical tests. Dirk J. Van Veldhuisen, of the Department of Cardiology/Thoracic Surgery, University Medical Center in the Netherlands said in a statement, “These results are especially encouraging because currently, there are no approved treatments to address the debilitating effects of anemia associated with symptomatic heart failure.”

Featured Articles

Related Articles